- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01069809
Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption
January 23, 2017 updated by: Argos Therapeutics
A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption
The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals.
Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals.
Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication
Study Type
Interventional
Enrollment (Actual)
53
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 816
- The Ottawa Hospital
-
-
Quebec
-
Montréal, Quebec, Canada, H2L4P9
- Clinique médicale l'Actuel
-
Montréal, Quebec, Canada, H2L5B1
- Clinique Médical du Quartier Latin
-
Montréal, Quebec, Canada, H2X 2P4
- Montreal Chest Institute, Immunodeficiency Dept.
-
-
-
-
California
-
Sacramento, California, United States, 95811
- UCDavis Research Office at CARES
-
-
New York
-
Bronx, New York, United States, 10461
- Jacobi & North Central Bronx Hospitals
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- AIDS Clinical Trials Unit
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 191002
- Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females ≥ 18 to 60 years of age.
- HIV infection.
- Stable ART regimen for ≥ 3 months prior to Screening.
- HIV VL level ≤ 400 copies/mL for ≥ 2 months prior to Screening.
- HIV VL level ≤ 50 copies/mL at Screening.
- CD4+ T cell count ≥ 450 cells/mm3 at Screening.
- Pre-ART nadir CD4+ T cell counts ≥ 200 cells/mm³.
- Availability of an adequate sample of frozen plasma most recently collected (no more than 90 days and preferably within 30 days) before starting ART.
- Laboratory values within pre-defined limits at Screening and Eligibility.
- Negative serum pregnancy test at Screening and Eligibility for females with reproductive potential, and agreement of all subjects to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug.
- Able and willing to give adequate written informed consent, to communicate effectively with study personnel, and willing to be compliant with protocol requirements.
Exclusion Criteria:
- HIV-2 antibody positive at Screening Visit.
- Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody (if positive HCV antibody, HCV RNA must be negative).
- Untreated syphilis infection (positive rapid plasma reagin [RPR]).
- Changes in ART regimen due to virologic breakthrough.
- History of lymph node irradiation or dissection.
- Prior use of any HIV immunotherapy or vaccine within 9 months prior to Screening.
- Prior participation in an AGS-004 clinical study.
- Treatment interruption of ART for > 1 month since starting the ART from which the pre-ART plasma sample was drawn.
- Any acute infection or medical illness within 14 days prior to Screening and throughout the pre-treatment evaluation phase (Step 1).
- Initiation of ART during the acute HIV infection stage, if date of infection known (acute infection defined as < 6 months between date of HIV infection and ART start date).
- Pregnancy or breast-feeding.
- Receipt of any immune modulators or suppressors within 30 days prior to Screening and throughout the pre-treatment evaluation phase (Step 1).
Evidence of hepatic decompensation in cirrhotic subjects: history of ascites, hepatic encephalopathy, or bleeding esophageal varices, or screening laboratory results of any of the following:
- International Normalized Ratio (INR) of ≥ 1.5 X upper limit of normal (ULN);
- Serum albumin < 3.3 g/dL;
- Serum total bilirubin > 1.8 X ULN, unless history of Gilbert's disease or deemed related to treatment with atazanavir.
- History or other clinical evidence of significant or unstable cardiac disease (e.g., angina, congestive heart failure, recent myocardial infarction, significant arrhythmia) or clinically significant electrocardiogram (ECG) abnormalities.
- History of moderate or severe renal impairment (i.e., persistent history of creatinine clearance < 50 mL/min) or any other renal disorder deemed clinically significant by the investigator.
- Prior history of an acquired immunodeficiency syndrome (AIDS) defining condition.
- History or other evidence of severe illness, malignancy, immunodeficiency other than HIV, or any other condition that would make the subject unsuitable for the study in the opinion of the investigator.
- Known allergy or sensitivity to the components of the investigational immunotherapy.
- Active drug or alcohol use or dependence that would interfere with adherence to study requirements in the opinion of the investigator.
- Use of systemic corticosteroids and use of topical steroids over a total area exceeding 15 cm² within 30 days prior to Screening.
- Any investigational antiretroviral agents or use of a CCR5 inhibitor at Screening.
- Active autoimmune disease or condition.
- Participation in another investigational clinical study within the previous 30 days or use of investigational agents.
- Body weight less than 30 kg.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AGS-004
HIV-1 Immune Therapy
|
HIV-1 Immune Therapy
|
Placebo Comparator: Inactive Injection
Inactive Placebo Injection
|
Inactive Placebo Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Compare the anti-HIV effects of AGS-004 versus Placebo as measured by new HIV Viral Load setpoint after a 12 week Analytical Treatment Interruption
Time Frame: 38 weeks
|
38 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate AGS-004 versus Placebo for change in plasma HIV Viral Load levels from the value just before initiation of ART to the value at the end of the 12 week ATI.
Time Frame: 38 weeks
|
38 weeks
|
Evaluate AGS-004 versus Placebo for change from Baseline in CD4 T-Cell absolute and percentage values at Week 26 and at the end of Step 4 (for subjects continuing ATI)
Time Frame: 38 weeks (62 weeks for subjects continuing ATI in Step 4)
|
38 weeks (62 weeks for subjects continuing ATI in Step 4)
|
Evaluate AGS-004 versus Placebo for effects on HIV viral kinetics during the 12 week ATI, as measured my mean or median levels of plasma HIV Viral Load; assessed throughout and at the end of Step 4 (for subjects continuing ATI)
Time Frame: 38 weeks (62 weeks for subjects continuing ATI in Step 4)
|
38 weeks (62 weeks for subjects continuing ATI in Step 4)
|
Evaluate AGS-004 versus Placebo for change from Baseline in TEAEs, clinical laboratory evaluations, and clinical assessments.
Time Frame: 2 years
|
2 years
|
Evaluate AGS-004 versus Placebo for change in inflammatory markers over treatment period and ATI
Time Frame: 38 Weeks (62 weeks for subjects continuing ATI in Step 4)
|
38 Weeks (62 weeks for subjects continuing ATI in Step 4)
|
Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline in T-cell response.
Time Frame: 2 years
|
2 years
|
Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline of the extent of viral evolution.
Time Frame: 2 years
|
2 years
|
Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline in the chromosomally integrated viral reservoir.
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jeffery Jacobson, MD, Drexel University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2010
Primary Completion (Actual)
August 1, 2014
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
February 16, 2010
First Submitted That Met QC Criteria
February 16, 2010
First Posted (Estimate)
February 17, 2010
Study Record Updates
Last Update Posted (Estimate)
January 24, 2017
Last Update Submitted That Met QC Criteria
January 23, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AGS-004-003
- HHSN266200600019C (Other Identifier: NIH Contract)
- ES-11702 (Other Identifier: DAIDS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on AGS-004
-
McGill University Health Centre/Research Institute...Université de Montréal; Argos TherapeuticsCompletedAcquired Immunodeficiency Syndrome | HIV SeropositivityCanada
-
Argos TherapeuticsCompletedHIV InfectionsCanada, United States
-
Cynthia L Gay, MDNational Institute of Allergy and Infectious Diseases (NIAID); Argos TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)TerminatedHIV-1 InfectionUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedMosquito-Borne DiseaseUnited States
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
BiocadRecruitingSpinal Muscular Atrophy (SMA)Belarus, Russian Federation
-
Genocea Biosciences, Inc.CompletedStreptococcus PneumoniaeUnited States
-
Agensys, Inc.CompletedCarcinoma, Renal Cell | Renal Cell Carcinoma of Papillary Histology | Renal Cell Carcinoma With Clear Cell Histology | Renal Cell Carcinoma With Non-Clear Cell HistologyUnited States, Canada
-
Astellas Pharma IncAgensys, Inc.CompletedCarcinoma | Ovarian Diseases | Ovarian Neoplasms | Ovarian CancerUnited States